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Abstract
Background
Most studies provide evidence that the skin flush response to nicotinic acid (niacin) stimula-
tion is impaired in schizophrenia. However, only little is known about niacin sensitivity in the
ultra-high risk (UHR) phase of psychotic disorders.
Methods
We compared visual ratings of niacin sensitivity between adolescents at UHR for psychosis
according to the one year transition outcome (UHR-T n = 11; UHR-NT n = 55) with healthy
controls (HC n = 25) and first episode schizophrenia patients (FEP n = 25) treated with atyp-
ical antipsychotics.
Results
Contrary to our hypothesis niacin sensitivity of the entire UHR group was not attenuated,
but significantly increased compared to the HC group, whereas no difference could be
found between the UHR-T and UHR-NT groups. As expected, niacin sensitivity of FEP was
attenuated compared to HC group. In UHR individuals niacin sensitivity was inversely corre-
lated with omega-6 and -9 fatty acids (FA), but positively correlated with phospholipase A2
(inPLA2) activity, a marker of membrane lipid repair/remodelling.
Conclusions
Increased niacin sensitivity in UHR states likely indicates an impaired balance of eicosa-
noids and omega-6/-9 FA at a membrane level. Our findings suggest that the emergence of
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psychosis is associated with an increased mobilisation of eicosanoids prior to the transition
to psychosis possibly reflecting a “pro-inflammatory state”, whereas thereafter eicosanoid
mobilisation seems to be attenuated. Potential treatment implications for the UHR state
should be further investigated.
Introduction
The observation that human kind responds with a red flush reaction of the upper body after
intake of large doses of nicotinic acid (niacin, vitamin B3) goes back to the early fifties of the
last century [1] a time when nicotinic acid was introduced as possible treatment of schizophre-
nia [2] While controlled studies failed to demonstrate a sustained clinical benefit of niacin in
schizophrenia treatment [3] the clinical observation of an attenuated or even absent niacin
flush reaction of the upper body in patients with schizophrenia compared to healthy controls
caught the attention of some researchers [4,5]. The latter observation combined with other
clinical observations such as that patients with schizophrenia are less sensitive to pain [6], have
a lower temperature sensitivity [7] and a markedly decreased risk of rheumatoid arthritis [8],
led to the proposal that schizophrenia might be associated with a deficiency or dysfunction of
prostaglandin metabolism [9]. Prostaglandins are metabolites of arachidonic acid (AA), a key
modulator of signal transduction [10]. The latter in conjunction with the observation that in
particular AA levels are reduced in post mortem and peripheral red blood cell membranes in
schizophrenia [11] lead to the formulation of the membrane and phospholipid hypothesis of
schizophrenia [12,13].
The pathway underlying the niacin skin reaction includes the activation of G protein-cou-
pled nicotinic acid receptors on skin macrophages and epidermal Langerhans cells that release
AA from membrane phospholipids. As a next step a sequential oxidation of AA, and (to
smaller quantities) also of dihomogamma-linolenic (DGLA) or eicosapentaenoic acid (EPA)
by cyclooxygenases (COX-1 and COX-2) follows. Finally, prostaglandin synthases are respon-
sible for the formation of a range of prostaglandins (e.g. D2, E2) that stimulate the production
of cyclic AMP, which in turn triggers capillary vasodilatation and increase regional blood flow,
observable as regional skin flushing [14,15].
A recent systematic review identified over 30 niacin sensitivity studies in schizophrenia and
related disorders [16]. The majority of studies using the topical variant of the niacin skin test
[17] reported that 23% up to 90% of patients with schizophrenia have an attenuated or absent
flush reaction compared to less than 0–25% of the normal population [17–22]. Niacin sensitiv-
ity seemed to be more attenuated in first-episode than in multi-episode schizophrenia patients
[23], raising the question if altered niacin sensitivity, as well as altered PUFAs and eicosanoid
metabolism may be more relevant for the onset of psychosis than for chronic illness stages.
The identification of young people with a high risk for schizophrenia and other psychotic
disorders has become a worldwide focus of attention [24]. Different clinical approaches have
been applied to identify young people with an at risk mental state for psychosis, such as the
Melbourne ultra-high risk (UHR) criteria [25–27] and the basic symptom concept [28,29]. To
our knowledge at the current state of research only clinically defined approaches found their
way into clinical daily routine and are able to identify help-seeking young people with an about
20% risk (with a range between 10–50%) to progress to a full-blown psychotic disorder within
one year [30]. Most clinicians would agree that clinically defined help-seeking UHR individuals
already need some kind of treatment, or at least intensive monitoring. However, there is also a
clear need to further optimize the so far available UHR criteria. Following this demand, a range
of biological markers, such as structural [31–33] and functional [34] imaging,
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neuropsychological [35], metacognitive [26,36,37] and electrophysiological [38] risk markers
have been proposed. To our knowledge, alterations of niacin sensitivity in UHR populations
have never been systematically investigated in this context. The few niacin sensitivity studies in
first-degree relatives of patients with schizophrenia (with no drop in functioning in contrast to
the UHR genetic liability subgroup) are inconclusive [14,39].
Therefore, our first aim in this study was to investigate niacin sensitivity in adolescents
meeting the Melbourne UHR criteria compared to first episode psychosis patients (FEP), who
meet criteria for schizophrenia or schizophreniform disorder, as well as to healthy controls
(HC). Our second aim was to investigate if baseline niacin sensitivity differed between those
who progressed towards psychosis (converters) versus those who did not (non-converters).
Our third aim was to address the relationship of niacin sensitivity with other markers of phos-
pholipid and fatty acid (FA) metabolism established in schizophrenia research, such as intra-
cellular phospholipase A2 (inPLA2) activity and membrane mono- and polyunsaturated fatty
acid (MUFA, PUFA) profile, within the UHR sample.
Based on previous findings in patients with established diagnosis of schizophrenia, where
the majority of studies found attenuated niacin sensitivity [16,40], increased inPLA2 activity in
blood plasma and post mortem brain tissue [41,42] and decreased PUFA levels [43–46], we
postulated the following a priori hypotheses that: I) niacin sensitivity of our UHR sample will
be attenuated, however to a lower extend than in FEP (in-between HCs and FEP), II) in the
UHR sample niacin sensitivity will be positively correlated with membrane omega-6 fatty acid
levels, in particular with arachidonic acid (AA), i.e. the lower the AA level, the weaker the nia-
cin skin response, and III) niacin sensitivity will be negatively correlated with inPLA2 activity,
i.e. the lower the niacin sensitivity, the higher the inPLA2 activity. IV) based on our recent find-
ings of a dynamic interrelation between inPLA2 activity and PUFA levels between UHR non-
transition (UHR-NT) and UHR transition (UHR-T) patients [47] we expected that niacin sen-
sitivity will be more attenuated in the UHR-T group than in the UHR-NT group.
Methods
Participants
UHR subjects were recruited at the early psychosis detection unit of the Department of Child
and Adolescent Psychiatry, Medical University of Vienna. All of them met UHR criteria for
psychosis and participated in a randomised placebo-controlled trial (RCT) that investigates the
influence of a 12 weeks omega-3 fatty acid supplementation (1.2g/d, including 700mg eicosa-
pentaenoic acid (EPA) and 480mg docosahexaenoic acid (DHA)) on transition status, psycho-
pathology and functioning within 12 month. In this study we present findings in baseline data
of this RCT.
Among the inclusion and exclusion criteria, previously published in detail in the original
publication of clinical findings [48], the following exclusion criteria were added for the niacin
skin tests study: 1) recent use of non-steroidal anti-inflammatory drugs, 2) dermatological ill-
ness, such as psoriasis, eczema, atopical dermatitis, 3) medical illness that would affect normal
vascular tone or response to niacin stimulus, such as inflammations, vasculitis, diabetes, or
chronic hypertension, 4) non-Caucasian skin type and 5) low-quality photographs (insufficient
sharpness, inappropriate exposure) that would prohibit “double-blind” ratings of the photo-
graphic documentation of the niacin skin reaction.
All consecutive referrals between April 2004 and May 2006 to the early detection unit of the
University Hospital of Vienna were considered for inclusion. Two hundred fifty-six individuals
were assessed for eligibility, 81 of whommet the inclusion criteria and consented to the original
RCT (for details see [48]). A total of 65/81 UHR subjects in turn met the above mentioned
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requirements for the niacin skin test study. Detailed demographic information of this sample is
provided in Table 1.
The institutional Research & Ethics Committee of the Medical University of Vienna, Aus-
tria, approved the study (EK-Nr.415/2002). All subjects (and for subjects under the age of 18
also their parents or legal guardians) gave written informed consent for the clinical interviews,
the niacin sensitivity skin test, as well as for all performed biochemical analyses.
We also included a data set of 25 first-episode patients (FEP) in our analysis, all fulfilling
DSM-IV criteria for schizophreniform psychosis or schizophrenia in order to perform a cross-
sectional comparison between UHR and FEP subjects. These patients were investigated at the
in- or outpatient clinic of Orygen Youth Health in Melbourne, Australia, using the same test
protocol as at the Medical University Vienna, which was applied by the same researcher (St.S)
and with the same equipment as in Vienna. Diagnosis, in- and exclusion criteria were con-
firmed by two independent experienced psychiatrists (St.S and G.B). Patients had a mean dura-
tion of illness of 14.5 months prior to performing the niacin skin test. All FEP patients were
treated with atypical antipsychotic medication (olanzapine: n = 12, mean dose 9.6 mg/d, range
2-20mg/d; risperidone: n = 10, mean dose 3.1 mg/d, range 1–5 mg/d; quetiapine: n = 2, 600 mg
and 800 mg/d; clozapine: n = 1, 300 mg/d).
We also included a niacin data set of 25 HC in our analysis, all recruited from staff of Ory-
gen Youth Health to perform a cross-sectional comparison between UHR, FEP und HC.
Table 1. Demographic and clinical characteristics of study participants.
UHR-NT UHR-T FEP HC
N 54 11 25 25
Gender (male/female) 18 (33.3%) 5 (45.5%) 17 (68.0%) 15 (60.0%)
Age (years) mean (±SD) 16.5 (±2.3) 16.4 (±1.3) 22.9 (±3.8) 32.9 (±7.4)
Nicotine
No 27 (50.0%) 5 (45.5%) 8 (32.0%) 23 (92.0%)
 10 cigarettes/d 13 (24.1%) 5 (45.5%) 10 (40.0%) 2 (8.0%)
> 10 cigarettes/d 15 (27.8%) 1 (9.1%) 7 (28%) 0
Alcohol
No 0 0 0 8 (32.0%)
Less than weekly 31 (57.4%) 6 (54.5%) 13 (52.0%) 10 (40.0%)
1–6 drinks/week 16 (29.6%) 2 (18.2%) 8 (32.0%) 5 (20.0%)
Daily 8 (14.8%) 3 (27.3%) 4 (16.0%) 2 (8.0%)
Marijuana
No 47 (87.0%) 9 (81.8%) 13 (52.0%) 25 (100%)
Less or equal 2 gr/week 4 (7.4%) 2 (18.2%) 12 (48.0%) 0
More than 2 gr/week 4 (7.4%) 0 0 0
Drugs other than THC 5 (9.3%) 2 (18.2%) 10 (40.0%) 0
Psychiatric medication
Antidepressants 20 (37.0%) 5 (45.6%) 4 (16.0%) 0
Antipsychotic agents 0 0 25 (100%) 0
Benzodiazepine or sedative 9 (16.7%) 10 (90.0%) 8 (32%) 0
Psychopathology
PANSS positive subscale 14.3 (±3.3) 15.6 (±2.5) 20.12 (±7.41) 0
PANSS negative subscale 12.8 (±5.1) 18.5 (±6.9) 18.96 (±8.63) 0
NT = non-transition, T = transition, FEP = ﬁrst-episode patient, HC = healthy control, all Caucasian
doi:10.1371/journal.pone.0148429.t001
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Current mental status, personal and family history of any mental disorder was assessed by the
same two trained psychiatrist (St.S und G.B.) as in the FEP sample. Volunteers were not eligible
as HC if they met any of the above mentioned exclusion criteria. FEP and HC were part of
another niacin sensitivity study which compared two different methods to asses skin flush
response (visual semi-quantitative vs optical reflection spectroscopy), and which included the
investigation of medication effects [22]. The Research and Ethic Committee of the North West-
ern Mental Health Network, Melbourne, Australia, approved this previous study. All partici-
pants gave written informed consent.
Assessment of niacin sensitivity
Ward et al [17] were the first who applied a topical variant of the niacin skin test in psychiatry
research. This test was further advanced to a test protocol that captures the information of
intensity and time-course of skin redness and oedema using a descriptive seven point rating
scale after stimulation with four niacin concentrations (0.0001M, 0.001M, 0.01M, and 0.1M),
and at four assessment time points (5, 10, 15 and 20 minutes post niacin application). The
descriptive rating scale defines 1 as no skin reaction, while 7 indicates intense redness with visi-
ble oedema that starts to spread out or oedema bigger than the patch area. The complete rating
scale is provided as S1 File named Berger Niacin rating scale in the Supporting Information.
Each rating was then entered in a matrix integrating all four concentrations and time points
(16 scores in total), and enabled the calculation of an overall sum score as well as subscores for
each concentration [22,49]. This descriptive assessment scale was evaluated using a method
quantifying the skin reaction by optical reflection spectroscopy (see above [22]). The latter was
not used in this study.
Using this test protocol, methylnicotinate (methyl pyridine-3-carboxylate, C7H7NO2, 99%,
Sigma-ALDRICH Chemistry GmbH, Steinheim, Germany) was applied simultaneously in four
dilutions (0.0001M, 0.001M, 0.01M, and 0.1M) of 50 μl each to four neighbouring places at the
inner side of the forearm using commercial chambered plaster for epicutaneous testing.
Methylnicotinate test solutions were freshly prepared for each test to prevent any influence of
sunlight. After 60 sec of skin exposure to methylnicotinate the plaster was removed. Skin reac-
tion was quantified before stimulation and in the areas of methylnicotinate exposure subse-
quently at 5-min intervals up to 20 minutes, starting 90 sec after removal of the
methylnicotinate patches.
Statistical analysis was performed on the individual overall sum scores of these 16 ratings
(possible min. /max. range between 16 and 112) in each participant, as well as on subscores for
each concentration.
Fatty acid analysis
Erythrocytes were separated from full blood to analyse fatty acid composition using the
phosphatidylethanolamine (PE) fraction, as PE is the most common glycerophospholipid at
the inner side of cerebral membranes. Using standard methods, values for saturated FA (SFA:
14:0, 16:0, 17:0, 18:0), monounsaturated fatty acids (MUFA including Trans-FA, TFAs: 18:1
(ω-7)tr, 18:1(ω-9)tr, and omega-9 fatty acids: 18:1(ω-9), 20:1(ω-9), 22:1(ω-9), 24:1(ω-9)), and
polyunsaturated fatty acids (PUFA including omega-6 fatty acids: 18:2(ω-6), 18:3(ω-6), 18:3
(ω-6), 20:3(ω-6), 20:4(ω-6), 22:2(ω-6), 22:4(ω-6), and omega-3 fatty acids: 18:3(ω-3), 20:5(ω-
3), 22:5(ω-3), 22:6(ω-3)) were obtained. More information on fatty acid analysis is provided in
the publication of [47] and in the S2 File named Laboratory analyses of the Supporting
Information.
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Intracellular Phospholipase A2 Activity (inPLA2)
InPLA2 activity in blood plasma was measured using a continuous kinetic fluorometric assay
with the commercially available fluorescent substrate PED6 (Cat. No. D23739; In-Vitrogen,
Carlsbad, California, USA). The assay strategy has been reported in the publication by Smesny
et al, 2014 [47] and is also provided in detail in the S2 File named Laboratory analyses of the
Supporting Information. Just briefly, PED6 incorporates a BODIPY1 FL dye-labelled sn-2 acyl
chain and a dinitrophenyl quencher group. Cleavage of the dye-labelled acyl chain by inPLA2
eliminates the intra-molecular quenching effect of the dinitrophenyl group, resulting in a cor-
responding fluorescence increase, which is directly linked to inPLA2 activity. For calculating
inPLA2 activities, the ascent of the fluorescence increase curve, the time interval after adding
PED6 (slope/min), and calibration curves (based on commercial bee venom PLA2) were used.
Resulting enzymatic activity was normalized to total protein concentration of the respective
plasma sample. This yields specific activity (pmol/min)/mg protein). In order to measure
inPLA2 requiring no or only a minimum amount of calcium, all measurements were conducted
in a calcium depleted environment, established by adding ethylene glycol tetraacetic acid
(EGTA) dissolution.
Statistical analysis
Group comparison of niacin sensitivity data. All analyses were performed in baseline
(pre-treatment) data of the original randomized controlled trial. As initial test we started with
a multivariate analysis of variance (MANOVA) including sum values of each niacin concentra-
tion (0.0001M, 0.001M, 0.01M, and 0.1M) and the total niacin sum score as dependent vari-
able, age (because being different between groups) as covariate and group (UHR non-
transition [UHR-NT] n = 55, UHR transition [UHR-T] n = 11, first-episode patients [FEP]
n = 25, healthy controls [HC] n = 25) as between-subject factor. Effects of single niacin concen-
trations were only considered if multivariate tests showed a significant effect of the factor
group. To evaluate effect sizes we calculated partial eta2, considering 0.01 as small, 0.06 as mod-
erate, and 0.14 as a large effect size.
We acknowledge the fact, that in all studies of our own group gender influenced the skin
flush intensity. Therefore we performed all test in the entire sample as well as in males or
females only. For the comparison of particular groups at particular niacin concentration we
performed post-hoc tests. We only present Bonferroni corrected results.
Correlational analyses. Associations between niacin scores and age as well as psychopa-
thology ratings were investigated by Pearson correlation analyses. In order to test for the
assumed associations between niacin sensitivity and other biological parameters, Pearson cor-
relation coefficients were calculated between niacin scores, sum values of fatty acid families
(sum values of PUFA and MUFA as well as of omega-3, omega-6 and omega-9 FA) or values
of single membrane fatty acids, and inPLA2 activity. The latter analysis was performed in UHR
individuals only. Because of the explorative character of this analysis, we did at this state of
knowledge not adjust for multiple tests.
Results
Sample characteristics
As expected, the mean age between the four groups was statistically significant different (F
(3,115) = 98.73, p<0.001) (see Table 1). Testing for differences in age by non-parametric tests,
significant differences could neither be found between the UHR-NT and UHR-T group, nor
between the FEP and HC group.
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The four groups did not differ in gender distribution (Chi-Square(3) = 6.826, p = 0.078).
However, as an influence of gender on niacin sensitivity has been reported several times by our
group, we present all results for the entire population, as well as for male or female subgroups.
Niacin sensitivity in UHR-NT, UHR-T, FEP and HC and associations
with psychopathology
Results of the multivariate and univariate tests of the initial MANOVA that was performed in
the entire population as well as in the male and female subgroup are summarized in Table 2.
Multivariate tests showed irrespective of gender a highly significant effect of the factor group
but neither the factor age nor the group by age interaction was significant. However, the sub-
group of females showed an influence of age on group effects at a trend level.
Also results of the univariate tests indicate highly significant group effects in all niacin con-
centrations irrespective of gender. Corresponding to multivariate findings, group effects in
females at the 0.01M and 0.1M niacin concentration are influenced by age.
To further explore the effect of age on niacin sensitivity, Pearson correlation analysis was
performed in the entire population as well as in males and females [50] (total population:
0.0001M r = -0.337, p<0.001; 0.001M r = -0.427, p<0.001; 0.01M r = -0.306, p = 0.001; 0.1M
r = -0.313, p = 0.001; total score r = -0.393, p<0.001; males: 0.0001M r = -0.364, p = 0.007;
0.001M r = -0.364, p = 0.007; 0.01M r = -0.206, p = 0.135; 0.1M r = -0.193, p = 0.162 total score
r = -0.342, p = 0.011; females: 0.0001M r = -0.247, p = 0.053; 0.001M r = -0.451, p<0.001;
0.01M r = -0.350, p = 0.005; 0.1M r = -0.374, p = 0.003; total score r = -0.385, p = 0.002).
Table 2. Analysis of variance with niacin scores as dependent variable, age as covariable and group as between-subject factor.
group age group by age
F p partial eta2 F p F p
multivariate tests
all 6.904 <0.001 0.201 1.471 0.216 1.019 0.431
males 3.670 <0.001 0.231 1.163 0.341 0.575 0.860
femals 4.878 <0.001 0.255 1.141 0.348 1.586 0.100
univariate tests
all 0.0001M 10.176 <0.001 0.216 1.807 0.176 0.658 0.580
0.001M 34.405 <0.001 0.482 0.404 0.526 0.703 0.552
0.01M 26.487 <0.001 0.417 1.010 0.317 1.723 0.132
0.1M 33.605 <0.001 0.477 0.743 0.390 1.361 0.259
total sum value 33.476 <0.001 0.475 0.004 0.949 0.917 0.435
males 0.0001M 5.661 0.002 0.254 0.413 0.524 0.261 0.853
0.001M 19.397 <0.001 0.538 1.675 0.202 0.727 0.541
0.01M 9.040 <0.001 0.352 0.698 0.408 0.335 0.800
0.1M 14.195 <0.001 0.460 1.669 0.203 0.574 0.635
total sum value 17.309 <0.001 0.509 0.467 0.498 0.216 0.884
females 0.0001M 9.972 <0.001 0.340 0.057 0.812 0.347 0.791
0.001M 29.827 <0.001 0.607 0.161 0.690 0.921 0.437
0.01M 24.554 <0.001 0.559 2.303 0.135 2.911 0.043
0.1M 26.052 <0.001 0.574 0.865 0.357 3.161 0.032
total sum value 27.497 <0.001 0.587 0.315 0.577 1.185 0.324
Multivariate and univariate test results of MANOVA with niacin scores included as dependent variable, age as covariable and group as between-subject
factor. Results are also presented for subgroups of males and femals. Bold numbers: results p < 0.05; italics: results at trend level p < 0.1.
doi:10.1371/journal.pone.0148429.t002
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Results of the post-hoc analyses corrected for multiple comparisons (Bonferroni) are sum-
marized in Table 3. In general, niacin sensitivity of UHR individuals irrespective of the transi-
tion outcome was significantly higher than in HC (and in FEP). This finding seems to be even
more pronounced in females. An illustration of the findings in total niacin scores of males and
females is given in Fig 1. As a replication of previous findings, in all but the lowest concentra-
tion’s (0.0001M) sum scores, the flush response was significantly lower in FEP than in HC,
equally apparent in males and females.
In UHR individuals there were no significant correlations between niacin flush scores and
psychiatric symptom scores.
Associations between niacin sensitivity and inPLA2 activity
The UHR group (n = 66) showed an inverse correlation between niacin sensitivity at 0.01M
and 0.001M and inPLA2 activity (0.01M Pearson’s r = -0.294, p = 0.017; 0.001M r = -0.264,
p = 0.034), i.e. decreased niacin sensitivity was associated with higher inPLA2 activity. As
Table 3. Bonferroni corrected results of post-hoc comparison of single groups as revealed by MANOVA.
all participants males females
mean SD mean SD p (corr.) mean SD mean SD p (corr.) mean SD mean SD p (corr.)
niacin UHR-NT
(n = 55)
HC (n = 25) UHR-NT
(n = 19)
HC (n = 15) UHR-NT
(n = 36)
HC (n = 10)
0.0001M 12.15 6.69 7.60 4.24 0.004 11.79 7.44 7.27 4.13 0.111 12.33 6.37 8.10 4.58 0.203
0.001M 16.98 4.09 10.84 3.69 <0.001 17.00 4.35 10.73 4.04 <0.001 16.97 4.01 11.00 3.30 <0.001
0.01M 21.67 3.14 17.92 3.03 <0.001 21.00 3.64 18.20 3.03 0.167 22.03 2.84 17.50 3.14 0.001
0.1M 25.20 2.32 21.92 2.83 <0.001 24.68 2.38 22.33 2.72 0.191 25.47 2.27 21.30 3.02 <0.001
Sum Score 76.00 14.10 58.28 9.91 <0.001 74.47 15.44 58.53 9.80 0.003 76.81 13.50 57.90 10.58 0.001
UHR-NT
(n = 55)
UHR-T
(n = 11)
UHR-NT
(n = 19)
UHR-T (n = 5) UHR-NT
(n = 36)
UHR-T (n = 6)
0.0001M 12.15 6.69 16.64 5.32 0.080 11.79 7.44 13.40 5.55 1.000 12.33 6.37 19.33 3.56 0.030
0.001M 16.98 4.09 19.18 4.35 0.533 17.00 4.35 17.20 4.87 1.000 16.97 4.01 20.83 3.43 0.153
0.01M 21.67 3.14 22.73 3.95 1.000 21.00 3.64 21.20 4.92 1.000 22.03 2.84 24.00 2.76 0.984
0.1M 25.20 2.32 26.09 2.47 1.000 24.68 2.38 25.00 3.39 1.000 25.47 2.27 27.00 0.89 1.000
Sum Score 76.00 14.10 84.64 14.58 0.240 74.47 15.44 76.80 17.08 1.000 76.81 13.50 91.17 8.89 0.074
UHR-NT
(n = 55)
FEP (n = 25) UHR-NT
(n = 19)
FEP (n = 15) UHR-NT
(n = 36)
FEP (n = 10)
0.0001M 12.15 6.69 5.32 2.39 <0.001 11.79 7.44 5.33 2.50 0.006 12.33 6.37 5.30 2.36 0.004
0.001M 16.98 4.09 6.88 3.33 <0.001 17.00 4.35 7.47 3.02 <0.001 16.97 4.01 6.00 3.74 <0.001
0.01M 21.67 3.14 14.32 3.90 <0.001 21.00 3.64 14.93 3.56 <0.001 22.03 2.84 13.40 4.40 <0.001
0.1M 25.20 2.32 18.20 3.81 <0.001 24.68 2.38 18.13 4.00 <0.001 25.47 2.27 18.30 3.71 <0.001
Sum Score 76.00 14.10 44.72 10.23 <0.001 74.47 15.44 45.87 8.56 <0.001 76.81 13.50 43.00 12.63 <0.001
FEP (n = 25) HC (n = 25) FEP (n = 15) HC (n = 15) FEP (n = 10) HC (n = 10)
0.0001M 5.32 2.39 7.60 4.24 0.831 5.33 2.50 7.27 4.13 1.000 5.30 2.36 8.10 4.58 1.000
0.001M 6.88 3.33 10.84 3.69 0.003 7.47 3.02 10.73 4.04 0.174 6.00 3.74 11.00 3.30 0.029
0.01M 14.32 3.90 17.92 3.03 0.002 14.93 3.56 18.20 3.03 0.094 13.40 4.40 17.50 3.14 0.033
0.1M 18.20 3.81 21.92 2.83 <0.001 18.13 4.00 22.33 2.72 0.003 18.30 3.71 21.30 3.02 0.074
Sum Score 44.72 10.23 58.28 9.91 0.001 45.87 8.56 58.53 9.80 0.047 43.00 12.63 57.90 10.58 0.063
Results are also presented for subgroups of males and females. Bold numbers: results p £ 0.05. Bold numbers: results p = 0.05; italics: results at trend
level p = 0.1.
doi:10.1371/journal.pone.0148429.t003
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outlined in Fig 2, this correlation was even more pronounced if the analysis included only
UHR-T individuals (n = 11; 0.001M r = -0.722, p = 0.028).
Associations between niacin sensitivity and fatty acid levels
In UHR individuals (irrespective of transition outcome) sum values of niacin concentrations
were not significantly correlated with sum values of omega-3 or omega-6 PUFA or omega-9
MUFA. However, niacin sensitivity correlated inversely with single omega-6 and omega-9 fatty
acids (see Table 4). In all UHR individuals (n = 66) the omega-6 FAs gamma-linolenic acid
(GLA, 18:3ω-6, precursor of arachidonic acid, AA) and docosadienoic acid (DSA, 22:2ω-6,
metabolite of AA) were inversely correlated with niacin flushing after 0.01M or 0.1M stimula-
tion. Of interest, GLA and DSA showed a significant positive correlation with inPLA2 activity
(GLA r = 0.266, p = 0.023; DSA r = 0.253, p = 0.042).
In omega-9 MUFA, three single FA (see Table 4) were inversely correlated with skin flush
response after 0.01M and 0.1M stimulation. Also oleic acid and eicosenoic acid were positively
correlated with inPLA2 activity (oleic acid r = 0.242, p = 0.052; eicosenoic acid r = 0.261,
p = 0.036).
Fig 1. Illustration of group differences of niacin scores between non-transition (NT) and transition (T)
UHR patients, first-episode psychosis patients (FEP) and healthy controls (HC). Due to obvious
(although not significant) differences in gender distribution between groups and previously reported effects of
gender on niacin skin sensitivity, results are presented separately for males and females. ** p<0.01.
doi:10.1371/journal.pone.0148429.g001
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Discussion
In summary, there were three main findings. First, in contrast to the results in established
schizophrenia and also to our initially formulated hypotheses, niacin sensitivity is not
Fig 2. Results of correlation analysis between niacin sum scores at 0.001M stimulation and inPLA2 activity in UHR-NT- and UHR-T individuals.
doi:10.1371/journal.pone.0148429.g002
Table 4. Correlation analysis between niacin sensitivity andmembrane fatty acid levels between all UHR individuals.
Omega-6 PUFA
Niacin 18:3ω-6 22:2ω-6
0.0001M n.s. n.s.
0.001M r = -0.263, p = 0.035 r = -0.260, p = 0.036
0.01M r = -0.328, p = 0.008 r = -0.358, p = 0.003
0.1M r = -0.340, p = 0.006 r = -0.346, p = 0.005
Sum Score n.s. n.s.
Omega-9 MUFA
18:1ω-9trans 20:1ω-9 20:3ω-9 22:1ω-9
0.0001M r = -0.247, p = 0.047 n.s. r = -0.250, p = 0.045 n.s.
0.001M r = -0.285, p = 0.021 n.s. r = -0.285, p = 0.021 n.s.
0.01M n.s. r = -0.337, p = 0.006 r = -0.299, p = 0.015 r = -0.364, p = 0.003
0.1M n.s. r = -0.329, p = 0.007 r = -0.333, p = 0.007 r = -0.356, p = 0.004
Sum Score r = -0.248, p = 0.046 n.s. n.s. n.s.
gamma-linolenic acid (18:3ω-6), docosadienoic acid (22:2ω-6), oleic acid (18:1ω-9trans), eicosenoic acid (20:1ω-9), mead acid (20:3ω-9), erucic acid
(22:1ω-9).
doi:10.1371/journal.pone.0148429.t004
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attenuated, but significantly increased in our UHR compared to HC and FEP groups (see Fig
1). Second, also contradictory to our hypotheses, within our UHR sample an inverse correla-
tions between niacin sensitivity and levels of single omega-6 and 9 fatty acids are present.
Finally, in line with our hypothesis lower niacin sensitivity is associated with a higher inPLA2
activity.
We believe that the finding of increased niacin sensitivity in conjunction with decreased
omega-6 and omega-9 FA in UHR individuals may be a signifier of a range of interrelated
pathomechanisms (e.g. oxidative stress) resulting in an increased demand of bioactive lipids or
an adaptive function associated with the emergence of psychosis. Having not investigated cere-
bral processes in this study, we speculate i) that an increased release/demand or an adaptive
down regulation of AA and (to a smaller extend) also DGLA could relate to an unspecific
“proinflammatory” process due to the excessive synaptic elimination and the associated prun-
ing {Feinberg, 1982 #1895;Feinberg, 1990 #1894;Keshavan, 1994 #1232;Farooqui, 2007 #9895;
[51] or ii) to excessive production of reactive oxygen species in the context of a weakened anti-
oxidative defense mechanisms, e.g. through a dysfunctional glutathione cycle [52–57].
Indeed, outside the central nervous system, AA and their bioactive lipids play a crucial role
for inflammatory processes. However, in the brain they are key players for the regulation of
neurodevelopment, long-term potentiation, synaptic plasticity and excitatory neurotransmis-
sion [58–60]. Having in mind the preliminary character of our findings, the inverse correla-
tions between niacin sensitivity (that occurs as a result of a prostaglandin mediated pathway)
and omega-6 or -9 FA could be interpreted as follows: Increased niacin sensitivity in UHR indi-
viduals could signify an increased demand for omega-6 FA (in particular for AA and its metab-
olites) and in the due course also for omega-9 FA resources, since monounsaturated omega-9
FA serve as compensatory replacements once omega-6 FA are exhausted [47]. Although pro-
viding some explanation for the increased niacin sensitivity in UHR individuals, this pathology
seems not yet very pronounced in our UHR sample, as inverse correlations were observed only
in single FA, but not in sum values of omega-6 FA, PUFA or MUFA. Thus, while bioactive lip-
ids and fatty acids seem to be still in balance in our UHR population due to effects of compen-
sation, the attenuated niacin sensitivity observed in FEP may then be the result of manifest
exhaustion of omega-6 FA resources and the incapacity to compensate the PUFA deficiency.
This interpretation is also supported by our observation of an inverse correlation between nia-
cin sensitivity and inPLA2 activity, and by the positive correlations between single omega-6
and omega-9 FA and inPLA2 activity respectively, as increasing inPLA2 activity is counted as
marker of up-regulated membrane lipid repair/remodeling processes [61] and was repeatedly
found in patients suffering schizophrenia [42].
Another line of research suggests that regulatory deficits in immune function are present in
schizophrenia and related disorders [62]. As mentioned earlier, niacin sensitivity is regulated
by prostaglandins (PGD2, PGE1), mainly metabolites of AA that is released by inPLA2 and fur-
ther metabolized mainly by COX-1 and COX-2. Considering this pathway, it is also possible
that increased niacin sensitivity may signify altered immunomodulatory activity in UHR indi-
viduals, i.e. prior to the onset of psychosis. Such an idea may also provide explanation for our
findings, and may support the idea that progression to acute psychosis is accompanied by
increased need of AA and its derivatives (such as eicosanoids) [63,64].
In contradiction to our hypothesis (IV), niacin sensitivity did not significantly differ
between UHR-transition (T) and -non-transition (NT) individuals. We also treat the difference
at trend level found at the lowest niacin concentration (0.0001M) with caution, as even the
solid finding of decreased niacin sensitivity in FEP got lost at this lowest niacin concentration.
Thus, the lowest niacin concentration seems to have in general the lowest sensitivity to disclose
group effects.
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A range of studies of our group investigating the underlying neurobiology of the emergence
of psychosis are in line with the proposed interpretations: First, using 1H-MR spectroscopy
imaging [65] omega-3 fatty acids induced the in vivo brain glutathione levels by 30%, a strong
intracellular antioxidants often induced during inflammation [55,66]. Furthermore T2 relaxa-
tion time [67], a very sensitive albeit unspecific marker of active potentially proinflammatory
processes, was increased in UHR individuals [65,67]. Second, nervonic acid, a monounsatu-
rated omega-9 FA crucially involved in myelination and a signifier of an exhaustion of proin-
flammatory metabolites, was decreased in UHR individuals, in particular in those suffering
transition to acute psychosis within one year [68]. Finally, early prenatal and/or perinatal expo-
sure to various environmental insults, including maternal exposure to stress, infections, nutri-
tional deficiencies as well as obstetric complications were found associated with increased
demands of PUFAs [51].
Our study has several limitations: Age and gender may be potential confounders, as niacin
sensitivity is generally more pronounced in females and attenuates gradually with age as shown
previously by our group [50]. This was also found in this study. In particular in females, age
significantly influenced group effects. Another potential confounder could be substance abuse
that was overexpressed in our UHR group. Our group was able to demonstrate an inverse asso-
ciation between niacin sensitivity and cannabis abuse (niacin sensitivity decreased in consum-
ing healthy controls) [69]. Furthermore, pharmacological treatment could have affected niacin
sensitivity. The use of antidepressants and benzodiazepines was higher in the treated UHR
group and therefore could have affected PUFA/oxylipin metabolism and the HPA-axis. As
effects of these agents on niacin sensitivity have not been shown or systematically investigated
as yet, a potential contribution to our results cannot be excluded at this stage of knowledge.
Furthermore, the UHR population is rather heterogeneous. Current evidence suggests that
niacin sensitivity is decreased in schizophrenia, may be also decreased to a lesser extend in uni-
polar depressive disorder, autism, dyslexia and hyperactivity disorder, but seems to be not
changed or even increased in manic episodes of bipolar affective disorders [16,70]. In depres-
sion, this pathology is linked to hypothalamic-pituitary-adrenal (HPA) axis dysfunction, show-
ing ongoing (nocturnal) ACTH and cortisol secretion (as caused by HPA axis hyperactivity) to
disturb the balance between omega-6 and omega-3 PUFA [71,72], which may in turn causes
down-stream effects on prostaglandin-mediated pathways. In the context of this study, the
findings that niacin flush response was positively correlated with severity of melancholic fea-
tures, anxiety, feelings of guilt and somatic concerns is interesting [70,73], depression is quite
common in UHR [74–76]. Therefore, niacin sensitivity in UHR individuals may be influenced
by the composition of the UHR population and the spectrum/severity of symptomatology. In
our particular UHR cohort from Vienna, most converters developed schizophrenia (see con-
sort diagram of the clinical trial publication by [48]), however this may not be the case in other
UHR populations. We were not able to show associations between niacin sensitivity and psy-
chopathology, presumably due to the limited range in symptom severity in this UHR sample.
For future niacin test studies, it could be important to stratify the study population according
to UHR subgroups, spectrum/severity of symptoms as well as according to the long-term
diagnosis.
In summary, in this study UHR subjects showed increased while FEP showed decreased sen-
sitivity to niacin [23]. The presented (weak) associations with omega-6- and omega-9 FA
metabolism and with PLA2 activity suggest niacin sensitivity may indicate that the UHR state
may be associated with a “pro-inflammatory state”. Future research should address the ques-
tion if the UHR state is associated with an incipient neurovulnerability that is associated with
bioactive lipid abnormalities and an activation of neuro-inflammatory processes. Potential
implications for neuroprotective treatments should be addressed. [67,77].
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